The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
14 / 207
Overall Ranking
107 / 4724
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Hold
Current Rating
111.880
Target Price
+8.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; biologics, sports medicine, extremities and trauma (S.E.T.) products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and ankle, among others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 290.58.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 21.51%.
Fairly Valued
The company’s latest PE is 25.04, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 190.39M shares, decreasing 2.58% quarter-over-quarter.
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; biologics, sports medicine, extremities and trauma (S.E.T.) products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and ankle, among others.